News
CSBTF
38.00
NaN%
--
Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion
TipRanks · 10/27 20:08
Kepler Capital Sticks to Their Buy Rating for Kuros Biosciences (CSBTF)
TipRanks · 10/18 01:45
Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion
Barchart · 10/17 00:34
Kepler Capital Sticks to Its Buy Rating for Kuros Biosciences (CSBTF)
TipRanks · 09/21 01:35
Weekly Report: what happened at CSBTF last week (0908-0912)?
Weekly Report · 09/15 11:45
Kuros Biosciences (CSBTF) Receives a Buy from Kepler Capital
TipRanks · 09/10 01:35
Weekly Report: what happened at CSBTF last week (0901-0905)?
Weekly Report · 09/08 11:47
Weekly Report: what happened at CSBTF last week (0825-0829)?
Weekly Report · 09/01 11:41
Weekly Report: what happened at CSBTF last week (0818-0822)?
Weekly Report · 08/25 11:55
Weekly Report: what happened at CSBTF last week (0811-0815)?
Weekly Report · 08/18 11:45
Kepler Capital Sticks to Their Buy Rating for Kuros Biosciences (CSBTF)
TipRanks · 08/16 01:46
Kuros Biosciences Reports Strong Revenue Growth in 2025
TipRanks · 08/15 04:04
Kuros Bioscience GAAP EPS of -$0.05, revenue of $63.48M misses by $19.35M; reaffirms FY outlook
Seeking Alpha · 08/14 13:27
Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025
TipRanks · 08/14 05:35
Weekly Report: what happened at CSBTF last week (0804-0808)?
Weekly Report · 08/11 11:54
Weekly Report: what happened at CSBTF last week (0728-0801)?
Weekly Report · 08/04 11:57
Weekly Report: what happened at CSBTF last week (0721-0725)?
Weekly Report · 07/28 11:58
Weekly Report: what happened at CSBTF last week (0714-0718)?
Weekly Report · 07/21 11:46
Weekly Report: what happened at CSBTF last week (0707-0711)?
Weekly Report · 07/14 11:57
More
Webull provides a variety of real-time CSBTF stock news. You can receive the latest news about Kuros Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About CSBTF
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.